Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  International Journal of Immunopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0192-0561(91)90112-KPMID 2071302
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma.

  1989cited by this paper
• Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats.

  1989cited by this paper
• Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis.

  1989cited by this paper
• Cardiac allograft survival in mice treated with IL-2-PE40.

  1989cited by this paper
• Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.

  1988cited by this paper
• Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor.

  1988cited by this paper
• IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors.

  1988cited by this paper
• Purification and Partial Characterization of an Interleukin 2-Pseudomonas Exotoxin Fusion Protein

  1988cited by this paper
• Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.

  1988cited by this paper
• Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli.

  1987cited by this paper
• Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin.

  1987cited by this paper
• Monoclonal anti-IL-2 receptor antibody in primate renal transplantation.

  1987cited by this paper
• Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

  1986cited by this paper
• Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats.

  1986cited by this paper
• Evidence for enhanced interleukin 2 (IL-2) secretion and IL-2 receptor presentation by synovial fluid lymphocytes in rheumatoid arthritis.

  1986cited by this paper
• Induction of experimental autoimmune uveoretinitis by T-cell lines.

  1986cited by this paper
• In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis.

  1985cited by this paper
• Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques.

  1984cited by this paper
• Interactions between T lymphocyte subsets supported by interleukin 2-rich lymphokines produce acute rejection of vascularized cardiac allografts in T cell deprived rats.

  1984cited by this paper
• Induction of suppressor T cells by interleukin 2.

  1984cited by this paper
• Peripheral blood and intrathyroidal mononuclear cell populations in patients with autoimmune thyroid disorders enumerated using monoclonal antibodies.

  1983cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy

  2016cites this paper
• Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer

  2016cites this paper
• An in situ cross-linking hybrid hydrogel for controlled release of proteins.

  2012cites this paper
• Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases

  2011cites this paper
• Immunotoxins for targeted cancer therapy

  2006cites this paper
• Effect of IL‐2‐Bax, a novel interleukin‐2‐receptor‐targeted chimeric protein, on bleomycin lung injury 1

  2005cites this paper
• Immunotoxins for targeted cancer therapy.

  1998cites this paper
• Recombinant toxins in haematologic malignancies and solid tumours.

  1998cites this paper
• Administration of disulfide‐stabilized Fv‐immunotoxins B1(dsFv)‐PE38 and B3(dsFv)‐PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice

  1995cites this paper
• Interleukin 2-Pseudomonas exotoxin A (IL2-PE40) Chimeric protein for targeted immunotherapy and the study of immune responses

  1994cites this paper
• Pseudomonas Exotoxin and Recombinant Immunotoxins Derived from It

  1993cites this paper
• Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis.

  1993cites this paper
• Anti‐arthritic effects demonstrated by an interleukin‐2 receptor‐targeted cytotoxin (DAB486IL‐2) in rat adjuvant arthritis

  1992cites this paper
• In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis.

  1992cites this paper
• Recombinant toxins as novel therapeutic agents.

  1992cites this paper
• Pseudomonas exotoxin: recombinant conjugates as therapeutic agents.

  1992cites this paper
• Targeting growth factor receptors with fusion toxins.

  1992cites this paper
• Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice.

  1991influential citation